億勝生物公布2022年度業績
Mar 08, 2023 20:29 HKT |  |
|
Essex Bio-Technology Announces 2022 Annual Financial Results
Mar 08, 2023 20:28 HKT | |
|
“天然分子” 的葫蘆裡，給慢病埋的什麼藥？
Mar 03, 2023 09:48 HKT | |
|
“天然分子” 的葫芦里，给慢病埋的什么药？
Mar 03, 2023 09:47 HKT | |
|
亿胜生物与复宏汉霖签订治疗年龄相关性黄斑变性全球共同开发及独家许可协议之经修订协议
Feb 22, 2023 18:50 HKT | |
|
億勝生物與復宏漢霖簽訂治療年齡相關性黃斑變性全球共同開發及獨家許可協議之經修訂協議
Feb 22, 2023 18:49 HKT | |
|
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration
Feb 22, 2023 18:48 HKT | |
|
疫苗开发不断变化的全球格局：Novotech 和 Endpoints News 网络研讨会
Feb 16, 2023 08:00 HKT |  |
|
疫苗開發不斷變化的全球格局：Novotech 和 Endpoints News 網絡研討會
Feb 16, 2023 08:00 HKT | |
|
백신 개발 발전의 글로벌 환경: 노보텍 및 엔드포인트 뉴스 웨비나
Feb 16, 2023 08:00 HKT | |
|
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar
Feb 15, 2023 09:00 HKT | |
|
Novotech 全球报告：亚太地区稳健的 1 期试验增长
Feb 13, 2023 06:00 HKT | |
|
Novotech 全球報告：亞太地區穩健的 1 期試驗增長
Feb 13, 2023 06:00 HKT | |
|
노보텍 글로벌 보고서: 아시아 태평양 지역에서 1단계 임상시험의 확고한 성장
Feb 13, 2023 06:00 HKT | |
|
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
Feb 10, 2023 21:06 HKT | |
|
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
Feb 10, 2023 19:00 HKT | |
|
亚太地区细胞与基因研究：Novotech 的增长速度比世界其它地区快 50%
Feb 04, 2023 07:00 HKT | |
|
亞太地區細胞與基因研究：Novotech 的增長速度比世界其它地區快 50%
Feb 04, 2023 07:00 HKT | |
|
아시아 태평양 지역 세포유전자 연구: 노보텍이 세계의 나머지 모든 기관들보다 50% 더 빠르게 성장
Feb 04, 2023 07:00 HKT | |
|
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW
Feb 03, 2023 13:00 HKT | |
|